Extract

- To assess serum MenC-PS specific IgG levels at T0 (prior to vaccination) and at 1 month (T1) and 1 year (T2) after the second MenCC vaccination and determine whether there is a difference in IgG levels between the different age groups (persistence of vaccine induced antibody levels) - To assess serum bactericidal antibody assay (SBA) levels at T0 and at 1 month (T1) and 1 year (T2) after the second MenCC vaccination and determine whether there is a difference between the different age groups in the levels and the proportion of participants that have an SBA level of ≥8 (persistence of vaccine induced protective antibody levels). - To assess avidity of serum IgG antibodies and determine whether there is a difference in avidity between the different age groups

Inclusion criteria

• The vaccin administered in this study is used to prevent invasive disease caused by Meningococcal serogroup C

Links

• ictrp
• euctr